All In Biotech

Drug Trial Radar · NCT04493424

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

An Open-label, Long Term Safety Trial of Spesolimab Treatment in Patients With Palmoplantar Pustulosis (PPP) Who Have Completed Previous BI Spesolimab Trials

Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

108

Actual

Start

Sep 4, 2020

Primary completion

Jan 16, 2023

Study completion May 15, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jul 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab. Participants who benefited from spesolimab treatment in the previous studies can join this study. The purpose of this study is to find out how safe spesolimab is and whether it helps people with palmoplantar pustulosis in the long-term. Participants are in this study for up to 5 years. During this time they visit the study site every month to get spesolimab injections under the skin. At study visits, doctors check the severity of participants' palmoplantar pustulosis and collect information on any health problems of the participants.

Conditions

  • Palmoplantar Pustulosis

Interventions

  • SpesolimabDrug

    Spesolimab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Treatment Emergent Adverse Events (TEAEs)Time frame: From first administration of study drug until last administration of study drug + 112 days, up to 869 days.

Locations

66 sites in 14 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center, PC

    Birmingham, Alabama

  • University of Missouri Health System

    Columbia, Missouri

  • The Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Menter Dermatology Research Institute

    Dallas, Texas

  • University of Utah Health

    Murray, Utah

  • Paratus Clinical Research Woden

    Phillip, Australian Capital Territory, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Skin Health Institute Inc

    Carlton, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Brussels - UNIV Saint-Luc

    Brussels, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Dr. Irina Turchin PC Inc.

    Fredericton, New Brunswick, Canada

  • SimcoDerm Medical and Surgical Dermatology Centre

    Barrie, Ontario, Canada

  • The Guenther Dermatology Research Centre

    London, Ontario, Canada

  • Innovaderm Research Inc.

    Montreal, Quebec, Canada

  • CCBR Czech a.s.

    Pardubice, Czechia

  • Univ. Hospital Kralovske Vinohrady

    Prague, Czechia

  • Sanatorium Prof. Arenebergera

    Prague, Czechia

  • HOP l'Archet

    Nice, France

  • HOP Saint-Louis

    Paris, France

  • HOP Larrey

    Toulouse, France

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Germany

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Universitätsklinikum Schleswig-Holstein, Campus Kiel

    Kiel, Germany

  • University of Pecs

    Pécs, Hungary

  • Markusovszky University Teaching Hospital

    Szombathely, Hungary

  • Fujita Health University Hospital

    Aichi, Toyoake, Japan

  • Tokyo Dental College Ichikawa General Hospital

    Chiba, Ichikawa, Japan

  • Fukuoka University Hospital

    Fukuoka, Fukuoka, Japan

  • Gifu University Hospital

    Gifu, Gifu, Japan

  • Asahikawa Medical University Hospital

    Hokkaido, Asahikawa, Japan

  • Takagi Dermatological Clinic

    Hokkaido, Obihiro, Japan

  • Takamatsu Red Cross Hospital

    Kagawa, Takamatsu, Japan

  • Sagamihara National Hospital

    Kanagawa, Sagamihara, Japan

  • Kumamoto University Hospital

    Kumamoto, Kumamoto, Japan

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, Kyoto, Japan

  • Tohoku University Hospital

    Miyagi, Sendai, Japan

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.